Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Buffalo, New York 14263


Purpose:

RATIONALE: Photodynamic therapy uses a drug, such as HPPH, that is absorbed by tumor cells. The drug becomes active when it is exposed to light. When the drug is active, tumor cells are killed. PURPOSE: This phase I trial is studying the side effects and best dose of photodynamic therapy using HPPH in treating patients with recurrent dysplasia, carcinoma in situ, or stage I oral cavity cancer.


Study summary:

OBJECTIVES: Primary - To determine the maximum tolerated dose in the oral cavity of photodynamic therapy (PDT) using HPPH and 665 nm light in patients with recurrent dysplasia, carcinoma in situ, or stage I squamous cell carcinoma of the oral cavity. Secondary - To determine response of dysplasia, carcinoma in situ, and selected patients with T1 squamous cell carcinoma of the oral cavity using PDT with HPPH and 665 nm light. OUTLINE: This is a dose-escalation study of laser light dose therapy. Patients receive HPPH IV over 1 hour on day 1. Approximately 24 hours after receiving HPPH, patients undergo laser light treatment to the tumor bed on day 2. Patients with multicentric or large area confluent disease receive a second course of treatment at least 8 weeks later for lesions untreated at the first treatment session. After completion of study treatment, patients are followed at 1 week, 1 month, 3 months, and periodically thereafter.


Criteria:

DISEASE CHARACTERISTICS: - Biopsy-confirmed diagnosis of 1 of the following: - Mild to severe dysplasia - Carcinoma in situ (CIS) of the oral cavity - Carcinoma must be less than 3mm thick - Stage I (T1) squamous cell carcinoma of the oral cavity - Recurrent or primary disease - No T2 or greater squamous cell carcinoma, exophytic CIS, or dysplasia lesions PATIENT CHARACTERISTICS: - ECOG performance status 0-2 - Total bilirubin ≤ 2.0 mg/dL - Creatinine ≤ 2.0 mg/dL - Alkaline phosphatase ≤ 3 times the upper limit of normal (ULN) - SGOT ≤ 3 times ULN - Not pregnant - Fertile patients must use effective contraception - No porphyria or hypersensitivity to porphyrin or porphyrin-like compounds PRIOR CONCURRENT THERAPY: - Prior therapy of any type allowed - More than 4 weeks since prior and no concurrent chemotherapy or radiotherapy


NCT ID:

NCT00670397


Primary Contact:

Principal Investigator
Hassan Arshad, MD
Roswell Park Cancer Institute


Backup Contact:

N/A


Location Contact:

Buffalo, New York 14263
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 17, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.